Now granted, Mad Money’s Cramer
identified Celgene Corp. (CELG) as a company that “may fit the
bill,” but we all know that Cramer only publicly approves blue chip
companies. Based on his rationale, though, we would propose that a
“baby blue chip” Cramer should be looking at is Nuvilex
As Cramer notes, Celgene is addressing different types of cancer and disorders. Cramer is spot on looking for a company with a varied pipeline that can work on many indications, which independently can generate BILLIONS in annual sales. CELG is a great prospect if you want to wait maybe a decade to possibly see a doubling of your asset (shares are over $100 each) (and let’s not forget about the downside if drugs fail and generic competitors take market share).
Nuvilex, Inc. has boundless upside potential because its proprietary cell encapsulation technology is a true platform that has the potential to serve as a benefit to countless indications. At 7.6 cents per share the downside risk is nominal, which makes it even more attractive!
Jim Cramer thinks a novel pancreatic can.cer therapy is worth at least $2 BILLION a year…and that’s just a fraction of what is N U V I L E X (OTCQB: N.V.L.X)cell encapsulation therapy can address!The use of research materials issued by the author is done at your own risk. You are encouraged to do your own research before making any investment decision in regards to the secu rity discussed herein. The author has not been rewarded by any entity in connection with the distribution of these materials. You should presume that as of the date of this report or letter, the author, possibly along with or through our owners, affiliates, employees and/or consultants, (cooperatively referred to as the author) has a position in all company shares (and/or options of the shares) covered herein that is consistent with the position set forth in our report. In connection with NVLX, the author has taken a long position. Following the distribution of any report or letter, the author plans to continue engaging in trnsactns in the security covered herein, and we may be long, short, and/or neutral at any time hereafter regardless of our initial position and we preserve the right to procure or trade all or part of our position at any time without notice. This practice could end in our trading securities at any time before, during, and/or after the disbursement of this report. Disclaimer